Benefits include patient well-being and improved fibromyalgia symptoms and function

Risk for death was found to be exacerbated by comorbidities

One of five trials in the FDA review was positive; all three trials in the published literature were positive

Pharmacogenomic testing predicted to save the health system $956 million and bring health gains of 0.381 QALYs per patient

No difference seen in symptom reduction with linking tones to brain electrical activity versus random tones

Prevalence of melatonin consumption significantly higher for school-aged children, preteens versus preschool children

Overall, 45.8 percent of patients with iNHL are worried about prognosis; 31.2 percent perseverate on their prognosis

Study also identifies design features that can enhance effectiveness

Facing more adverse conditions has additive effect on risk for contemplating suicide

Association was independent of Aβ and tau, and accounted for 10 percent of the variance in cognitive decline